Oct 9, 2026 08:01AM
Sep 29, 2026 08:02AM
Aug 7, 2026 08:59AM
Jul 28, 2026 08:30AM
Jul 7, 2026 07:50AM
May 6, 2026 08:31AM
May 4, 2026 08:30AM Atossa gets FDA rare pediatric disease status for McCune-Albright drug
Mar 27, 2026 06:46AM
Mar 12, 2026 08:03AM
Feb 11, 2026 08:31AM
Feb 5, 2026 08:31AM
Jan 6, 2026 08:15AM
Dec 11, 2025 08:02AM
Dec 9, 2025 08:01AM Atossa receives US patent for endoxifen breast cancer formulations
Dec 8, 2025 04:46AM
Dec 5, 2025 06:46AM
Dec 4, 2025 08:01AM
Dec 2, 2025 08:01AM
Nov 17, 2025 09:09AM
Nov 12, 2025 04:23PM
Oct 14, 2025 07:53AM Atossa Therapeutics names Mark Daniel as chief financial officer
Oct 7, 2025 06:47AM
Oct 6, 2025 08:04AM
Oct 1, 2025 08:32AM
Sep 9, 2025 06:52AM
Sep 8, 2025 08:30AM
Aug 29, 2025 09:00AM
Aug 12, 2025 09:46AM Atossa Genetics (ATOS) Misses Q2 EPS by 1c
Aug 1, 2025 09:00AM
Jun 6, 2025 05:21AM
Jun 5, 2025 08:39AM
May 20, 2025 09:00AM
May 13, 2025 05:31PM
May 2, 2025 09:00AM
Apr 30, 2025 08:45AM Atossa Therapeutics (ATOS) Issued U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
Apr 29, 2025 08:47AM
Apr 22, 2025 08:45AM
Mar 26, 2025 06:52AM
Mar 11, 2025 08:15AM
Jan 30, 2025 08:17AM
Jan 23, 2025 08:15AM
Dec 11, 2024 08:15AM Atossa Therapeutics (ATOS) Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Nov 13, 2024 06:54AM
Nov 5, 2024 08:05AM
Nov 4, 2024 06:30AM
Oct 31, 2024 08:15AM
Sep 10, 2024 08:30AM
Aug 28, 2024 08:31AM
Aug 21, 2024 11:37AM Atossa Therapeutics (ATOS) and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Aug 21, 2024 08:37AM

479,040 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All